1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Pharma's Experiment With India's Borrow And Treat Model

 
• By Anju Ghangurde

When a 52-year-old Indian cart-seller of plastic toys was hospitalized because of a cardiac condition the first time, his family decided against going through with the treatment. They simply could not afford the costs involved.

When a 52-year-old Indian cart-seller of plastic toys was hospitalized because of a cardiac condition the first time, his family decided against going through with the treatment. They simply could not afford the costs involved.

But the second time round, when he was back in hospital, Arogya Finance, which offers medical loans to the "traditionally...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.